Journal ArticleDOI
Association of metformin use with cancer incidence and mortality: A meta-analysis
Reads0
Chats0
TLDR
Metformin can reduce the incidence of overall cancer, liver cancer, pancreatic cancer, colorectal cancer and breast cancer as well as the mortality of Overall cancer, Liver cancer and Breast cancer.About:
This article is published in Cancer Epidemiology.The article was published on 2013-06-01. It has received 242 citations till now. The article focuses on the topics: Cancer & Breast cancer.read more
Citations
More filters
Journal ArticleDOI
Thiazolidinediones, alpha-glucosidase inhibitors, meglitinides, sulfonylureas, and hepatocellular carcinoma risk: A meta-analysis.
TL;DR: In this article, the authors evaluated associations between sulfonylureas, thiazolidinediones, meglitinides and alpha-glucosidase inhibitors, and incident HCC risk.
Journal ArticleDOI
Metformin usage and the risk of colorectal cancer: a national cohort study
Jae-Woo Lee,Eun-A Choi,Ye-Seul Kim,Yonghwan Kim,Hyo-Sun You,Ye-Eun Han,Hyeong-Seop Kim,Yoon-Jong Bae,Joungyoun Kim,Hee-Taik Kang +9 more
TL;DR: Metformin users with diabetes appear to have a significantly lower risk of CRC compared with metformin non-users, according to a longitudinally analyzed database of data from the NHIS-HEALS cohort.
Journal ArticleDOI
Fructosamine and diabetes as predictors of mortality among Hispanic and non-Hispanic white breast cancer survivors
Avonne E. Connor,Kala Visvanathan,Stephanie D. Boone,Nader Rifai,Kathy B. Baumgartner,Richard N. Baumgartner +5 more
TL;DR: It is found that women with diabetes had a nearly 3-fold higher risk of dying from their breast cancer and more than a two-fold greater risk for all-cause mortality and better glucose management could improve outcomes for breast cancer survivors with diabetes.
Journal ArticleDOI
Effects of Metformin and Vitamin D on Clinical Outcome in Cholangiocarcinoma Patients.
Andrea Casadei-Gardini,Roberto Filippi,Margherita Rimini,Ilario Giovanni Rapposelli,Lorenzo Fornaro,Nicola Silvestris,Luca Aldrighetti,Giacomo Aimar,Giulia Rovesti,Giulia Bartolini,Caterina Vivaldi,Oronzo Brunetti,Elisa Sperti,Rosa La Face,Francesca Ratti,Kalliopi Andrikou,Martina Valgiusti,Laura Bernardini,Antonella Argentiero,Elisabetta Fenocchio,Giovanni Luca Frassineti,Silvia Cesario,Francesco Giovannelli,Virginia Quarà,Francesco Leone,Stefano Cascinu +25 more
TL;DR: In this paper, the authors investigated the role of intake of vitamin D, aspirin, metformin, statins, and diuretics in terms of clinical outcome of the common non-cancer medications.
Mechanisms of Action of Metformin as an Anti-cancer Agent
TL;DR: This paper presents a meta-anatomy of the determinants of infectious disease in eight operation rooms and some of the mechanisms leading to disease progression are described.
References
More filters
Journal ArticleDOI
Measuring inconsistency in meta-analyses
TL;DR: A new quantity is developed, I 2, which the authors believe gives a better measure of the consistency between trials in a meta-analysis, which is susceptible to the number of trials included in the meta- analysis.
Journal ArticleDOI
Bias in meta-analysis detected by a simple, graphical test
TL;DR: Funnel plots, plots of the trials' effect estimates against sample size, are skewed and asymmetrical in the presence of publication bias and other biases Funnel plot asymmetry, measured by regression analysis, predicts discordance of results when meta-analyses are compared with single large trials.
Journal ArticleDOI
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
TL;DR: Those on insulin or insulin secretagogues were more likely to develop solid cancers than those on metformin, and combination with met formin abolished most of this excess risk.
Journal ArticleDOI
New Users of Metformin Are at Low Risk of Incident Cancer: A cohort study among people with type 2 diabetes
Gillian Libby,Louise A. Donnelly,Peter T. Donnan,Dario R. Alessi,Dario R. Alessi,Andrew D. Morris,Josie M M Evans +6 more
TL;DR: Results suggest that metformin use may be associated with a reduced risk of cancer in people with type 2 diabetes, and a randomized trial is needed to assess whether met formin is protective in a population at high risk for cancer.
Journal ArticleDOI
Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
Andrea Decensi,Matteo Puntoni,Pamela J. Goodwin,Massimiliano Cazzaniga,Alessandra Gennari,Bernardo Bonanni,Sara Gandini +6 more
TL;DR: A comprehensive literature search and meta-analysis of epidemiologic studies to assess the effect of metformin on cancer incidence and mortality in diabetic patients found that the inverse association was significant for pancreatic and hepatocellular cancer, and nonsignificant for colon, breast, and prostate cancer.
Related Papers (5)
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level
I. Ben Sahra,Kathiane Laurent,Kathiane Laurent,Agnès Loubat,Agnès Loubat,Sophie Giorgetti-Peraldi,Sophie Giorgetti-Peraldi,Pascal Colosetti,Pascal Colosetti,Patrick Auberger,Patrick Auberger,Jean-François Tanti,Jean-François Tanti,Y. Le Marchand-Brustel,Y. Le Marchand-Brustel,Frédéric Bost,Frédéric Bost +16 more